Chemotherapy of advanced non small cell lung cancer in the elderly: An update

Critical Reviews in Oncology/Hematology

Volumn 35, Issue 3, 2000, Pages 219-225

  Gridelli, C ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Elderly; ELVIS; NSCLC; Phase III

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE;

AGED; AGING; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; NEPHROTOXICITY; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0033840307     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00064-5     Document Type: Article

References (42)

1. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using update on individual patients from 52 randomized clinical trials. Br. Med. J. 1995;311:899-909.
2. Silverberg E. Cancer statistics. CA J. 38:1988;5-22.
3. Gridelli C., Perrone F., Monfardini S. Lung cancer in the elderly. Eur. J. Cancer. 33:1997;2313-2314.
4. Havlik R.J., Yancik R., Long S., et al. The National Cancer Institute on Aging and the National Cancer Institute SEER. Collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer. 74:(suppl. 7):1994;2101-2106.
5. O'Rourke M.A., Feussner J.R., Feigl P., et al. Age trends of lung cancer stage at diagnosis. Implications for lung cancer screening in the elderly. J. Am. Med. Assoc. 258:1987;921-926.
6. Vercelli M., Quaglia A., Casella C., et al. Cancer patient survival in the elderly in Italy. Tumori. 83:1997;490-496.
7. Brown J.S., Eraut D., Trask C., et al. Age and treatment of lung cancer. Thorax. 51:1996;564-568.
8. Abram M. The health of the very elderly. Isaacs B. Recent Advances in Geriatric Medicine. 3:1985;217-226 Churchill Livingstone, Edinburgh.
9. Monfardini S. What do we know on variables influencing clinical decision-making in elderly cancer patients. Eur. J. Cancer. 32:1996;12-14.
10. Fentiman I.S., Tirelli V., Monfardini S., et al. Cancer in the elderly: why so badly treated. Lancet. 28:1990;1020-1022.
11. Rinaldi M., De Marinis F., Ardizzoni A., et al. Correlation between age and prognosis in patients with advanced non small cell lung cancer (NSCLC) treated with cisplatin (CDDP) containing chemotherapy: a retrospective multicenter study. Ann. Oncol. 5:(Suppl. 8):1994;58.
12. Kubota K., Hosomura K., Kakinuma R., et al. Cisplatin nephrotoxicity in elderly patients with lung cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;491A.
13. Oshita F., Kurata T., Kasai T., et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ function. Jpn. J. Cancer Res. 86:1995;1198-1202.
14. Soquet P.J., Bombaron P., Brunel-Crova J., et al. Treatment of advanced and disseminated non small cell lung cancer (NSCLC) in elderly patients: results of MIC regimen. Lung Cancer. 18:(Suppl. 1):1997;24.
15. Kubota K., Furuse K., Kawahara M., et al. Cisplatin-based combination chemotherapy for elderly patients with non small cell lung cancer. Cancer Chemother. Pharmacol. 40:1997;469-474.
16. Lippe P., Silva R.S., Monterubbianesi C., et al. Advanced non small cell (NSCLC) in the elderly: symptoms-reliefs after weekly gemcitabine (G) and cisplatin (P). Proc. Am. Soc. Clin. Oncol. 18:1999;514A.
17. Rosti G, Zumaglini F, Gridelli C, et al. Carboplatin and oral VP-16 in advanced lung cancer patients aged ≥70 years. A phase II trial. Second International Conference on Cancer in the Elderly, Genova 19-21 September 1994.
18. Thomas P, Castelnan O, Kleisbauer JP. Carboplatin plus oral etoposide in elderly patients with bronchogenic carcinoma. Preliminary results of a phase II trial. Second International Conference on Cancer in the Elderly, Genova, 19-21 September 1994.
19. Gridelli C., Rossi A., Scognamiglio F., et al. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study. Anticancer Res. 17:1998;4755-4758.
20. Imperatori L, Mattioli R, Casadei V, et al. Weekly carboplatin+fluorouracil+L folinic acid in advanced NSCLC of the elderly: efficacy in symptoms relief. Eight International Congress on Anti-Cancer treatment, Paris, 3-6 February, 1998.
21. Colleoni M, Vicario G, Pancheri F, et al. Weekly carboplatin and vinorelbine in elderly patients with non small cell lung cancer (NSCLC). Sixth International Congress on Anticancer Treatment; Paris, 6-9 February, 1996.
22. Santomaggio C., Righi R., Tucci E., et al. Chemioterapia con carboplatino (CBDCA) e vinorelbina (V) nell'anziano affetto da carcinoma polmonare con microcitoma, stadi avanzati (A-NSCLC). J. Chemother. 8:(Suppl. 3):1996;104.
23. Gallotti P., Chiesa E., Olgiati A., et al. Vindesine as monochemotherapy in non small cell lung cancer (NSCLC) in elderly patients. Ann. Oncol. 3:(Suppl. 5):1992;36.
24. Malarme M., Marcelis L., Kalas J.P., et al. Ifosfamide (IFO) and vindesine (VDS) therapy for non small cell lung cancer (NSCLC) in the elderly. Ann. Oncol. 3:(Suppl. 5):1992;36.
25. Salvati F., Antilli A., Cruciani A.R., et al. Lonidamine plus cyclophosphamide in the treatment of advanced non small cell lung cancer in the elderly: a phase II study. Tumori. 81:1995;48-51.
26. De Marinis F., Rinaldi M., Ardizzoni A., et al. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non small cell lung cancer: a phase III randomized FONICAP trial. Tumori. 85:1999;177-182.
27. Zaheer W., Lichtman S.M., De Marco L., et al. The use of taxol in elderly patients. Proc. Am. Soc. Clin. Oncol. 13:1994;441.
28. Rosvold E., Langer C.J., McAleer C., et al. Advancing age does not exacerbate toxicity or compromise outcome in non small cell lung cancer (NSCLC) patients (pts) receiving paclitaxel-carboplatin (P-C). Proc. Am. Soc. Clin. Oncol. 18:1999;478a.
29. Baldini E., Tibaldi C., Pfanner E., et al. Phase II study of oral doxifluridine in elderly patients with advanced non small cell lung cancer. Am. J. Clin. Oncol. 19:1996;592-594.
30. Martin C., Ardizzoni A., Rosso R. Gemcitabine: safety profile and efficacy in non small cell lung cancer unaffected by age. Aging. 9:1997;297-303.
31. Shepherd F.A., Abratt R.P., Anderson H., et al. Gemcitabine in the treatment of elderly patients with advanced non small cell lung cancer. Sem. Oncol. 24:(Suppl. 7):1997;50-55.
32. Tibaldi C, Ricci S, Bonifazi F et al.@ Preliminary results of a multicentre phase II study with gemcitabine monotherapy in the elderly patients with advanced non small cell lung cancer (NSCLC). Ann. Oncol. 1998;9(Suppl. 3):83.
33. Pasquini E., Tassinari D., Nicolini M., et al. Gemcitabine in advanced non small cell lung cancer (NSCLC): a valid option in geriatric patients. Lung Cancer. 24:1999;202.
34. Martoni A., Di Fabio F., Guaraldi M., et al. Gemcitabine as single agent in the treatment of elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): preliminary results of an Italian multicenter phase II study. Proc. Am. Soc. Clin. Oncol. 18:1999;517A.
35. Feliu J., Lopez-Gomez L., Madronal C., et al. Gemcitabine plus vinorelbine in non small cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer. 86:1999;1463-1469.
36. Colleoni M., Gaion F., Nelli P., et al. Weekly vinorelbine in elderly patients with non small cell lung cancer. Tumori. 80:1994;448-452.
37. Veronesi A., Crivellari D., Magri M.D., et al. Vinorelbine treatment of advanced non small cell lung cancer with special emphasis on elderly patients. Eur. J. Cancer. 32A:1996;1809-1811.
38. Tononi A., Panzini I., Oliviero G., et al. Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients. J. Chemother. 9:1997;304-308.
39. Gridelli C., Perrone F., Gallo C., et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non smalll cell lung cancer. A two-stage phase II study. Eur. J. Cancer. 33:1997;392-397.
40. The Elderly Lung cancer Vinorelbine Italian Study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J. Natl. Cancer Inst. 1999;91:66-72.
41. Aaronson N.K. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85:1993;365-376.
42. Monfardini S., Ferrucci L., Fratino L., et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer. 77:1996;395-401.